Wegovy plus exercise for weight loss: what the studies show

What did @leahkenyon5 actually say?

Leah says she started Wegovy in mid-October at 170.4 pounds and weighed in at 153.6 pounds at the time of filming, a loss of about 16.8 pounds. She's currently on the 1 mg dose and moving up to 1.7 mg, which she calls a "maintenance dose." She credits cleaning up her eating for resolving early GI side effects like sulfur burps and diarrhea, says her heartburn has gotten worse on the medication, and specifically calls out PCOS as the reason she struggled with stubborn weight before Wegovy. She got the prescription through her primary care doctor after trying other interventions first.

She also mentions losing weight first in her face and midsection, and jokes that breast fat has been spared. Nothing in here is wildly irresponsible, but a few details deserve a closer look.

Does the science back this up?

Mostly, yes. The STEP trial data for semaglutide is solid, and the PCOS connection she describes is well-supported in the literature. Her observation about GI side effects improving with better food choices is plausible, though the evidence there is less definitive.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks. Leah's ~10% loss at an earlier, lower dose is right in the expected range. On PCOS specifically, a 2022 meta-analysis by Jensterle et al. in Frontiers in Endocrinology found GLP-1 receptor agonists significantly reduced body weight, fasting insulin, and androgen levels in women with PCOS. Her description of "stubborn weight that would not come off" maps directly onto the insulin resistance that characterizes PCOS and that GLP-1 drugs directly address.

Her heartburn complaint is also documented. Semaglutide slows gastric emptying, and worsening gastroesophageal reflux is a recognized side effect, particularly in people with pre-existing GERD, which she says she has.

What did they get wrong (or right)?

The biggest inaccuracy is calling 1.7 mg "a maintenance dose." That's not really how Wegovy's titration schedule works. Wegovy's approved maintenance dose is 2.4 mg weekly. The 1.7 mg is a titration step, not where you stay. It's possible her doctor has a specific plan for her, but presenting 1.7 mg as a permanent stopping point could mislead viewers into thinking they're done escalating when they may not be.

Her theory that GI side effects were caused entirely by "eating bad" is partially right but oversimplified. Fatty, rich, or high-fiber foods can worsen semaglutide-related nausea and diarrhea, and dietary changes do help. But some people experience significant GI symptoms regardless of diet, especially during dose escalation. Framing it as purely a diet quality issue could cause viewers to blame themselves if side effects persist after cleaning up their eating.

On the other hand, her point about weight loss pattern (face first, then midsection) and her honest admission that she doesn't fully understand the drug's mechanism are refreshingly accurate self-assessments. She's not overclaiming.

What should you actually know?

If you have PCOS and are considering a GLP-1 medication, the evidence is genuinely encouraging, but there are things Leah's video doesn't cover. First, semaglutide is not approved specifically for PCOS. It's approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). Use in PCOS is off-label, even if increasingly common and supported by emerging data.

Second, the heartburn issue she mentions is worth taking seriously. People with pre-existing GERD who take semaglutide should be monitored for worsening symptoms. A 2023 study by Sodhi et al. in JAMA found GLP-1 receptor agonists were associated with increased risk of gastroparesis compared to other weight loss medications. If you already have heartburn, tell your prescriber before starting.

Third, stopping Wegovy typically leads to weight regain. The STEP 4 trial (Rubino et al., 2021, JAMA) found participants regained about two-thirds of their lost weight within a year of stopping. Leah says she'll be on 1.7 mg "for however long" and admits "I don't really know how it works." That honesty is fine for a personal update video, but anyone watching should understand this is likely a long-term medication, not a short course.

Bottom line on this video

This is a personal update, not medical advice, and Leah is mostly careful about framing it that way. Her results are plausible and her experience with PCOS aligns with what researchers are finding. The two things to correct: 1.7 mg is not a maintenance dose under Wegovy's standard protocol, and GI side effects aren't purely a diet problem. Everything else she describes is consistent with how this drug actually works.